SBIR/STTR Research Award

A microchip to analyze trafficking leukocytes in Alzheimer’s disease patients

Award identifier 8340e4c8e4a0c0f709110302f00adc06c5ed8001ecbef8dc0ec4da1c36cca619Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$164,016

Program and phase

SBIR · Phase I

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ISOPLEXIS CORPORATION
Proposal award date
2016-06-01
Contract end date
2016-11-30
UEI
FRM2JMLMGJK1
Solicitation number
PA15-052
Topic code
NIA

Research abstract

DESCRIPTION provided by applicant Alzheimerandapos s disease AD is one of the most common neurodegenerative diseases that lead to detrimental outcomes such as progressive memory deficit and cognitive impairment Although it is expected that the prevalence of AD will double over the next years currently no widely accepted molecular biomarkers for early detection or non invasive monitoring of AD There has been increasing evidence that immune responses and brain inflammation are involved in the pathogenesis of neurodegenerative disorders in the central nervous system CNS The immune cells participating in the inflammatory response in the deep brain often get into cerebrospinal fluid CSF so called the andquot circulatoryandquot system of CNS and these cells carry the information about deep brain inflammatory pathology On the other hand while the blood brain barrier BBB restricts the entry of immune cells into the CNS a small number of immune cells can traverse into the CNS during pathophysiological states to participate in immune surveillance Excessive migration or abnormal functioning of these immune cells contribute to the development of neurodegenerative pathology It has been hypothesized that these trafficking leukocytes in CSF are potential cell markers to detect and measure inflammatory neurodegenerative disease However it remains challenging due to i the paucity of trafficking leukocytes cell microliter and the high degree of cellular heterogeneity with diverse immune effector functions proteins secreted by cells up to IsoPlexis has a prototype hand held technology that for the first time provides the ability to measure many up to of these key effector proteins at the single cell level At the same time this device in its envisioned form requires much less amount of cell input representing a major advantage over the existing single cell instruments e g flow cytometer for the specific application toward the analysis of rare trafficking leukocytes It will also be far less costly tha existing single cell instruments representing a significant market advantage Thus we plans to develop a fully integrated system that incorporates the enrichment of trafficking leukocytes using nanorough surfaces and single cell effector protein analysis on the same microdevice to truly enable the opportunity for wide spread use of trafficking leukocytes as the biomarker for early stage diagnosis and monitoring of inflammatory neurodegenerative diseases specifically AD To reach this goal we propose Incorporating a cell capture module in the IsoPlexis microdevice to perform on chip separation of low abundance leukocytes followed by highly multiplexed immune function analysis Develop an integrated carrier device to perform reliable operation of the integrated microchip for measuring rare trafficking leukocytes from CSF We expect to develop a unique and minimally invasive approach to quantitatively measure inflammatory conditions in deep brain for early diagnosis and therapeutic monitoring of AD using CSF This approach will also have broad impact on preclinical or clinical uses for routine screening or monitoring of inflammatory neurodegenerative diseases PUBLIC HEALTH RELEVANCE We propose to develop a fully integrated system that incorporates the enrichment of trafficking leukocytes from cerebrospinal fluid CSF using nanorough surfaces and single cell effector protein analysis on the same microdevice to truly enable the opportunity for wide spread use of trafficking leukocytes as the biomarker for early stage diagnosis and monitoring of inflammatory neurodegenerative diseases specifically Alzheimerandapos s disease This unique approach is minimally invasive and will have broad impact and unique value for preclinical or clinical uses for routine screening or monitoring of inflammatory neurodegenerative diseases

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

17 SBIR/STTR records share this UEI (2015–2020). Reported award amounts total $18,897,114. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.